MedTrace Logo

Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis

NCT03310320 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2019-04-25

No results posted yet for this study

Summary

The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales. The severity of the disease varies, but in many cases it can have a major impact on their quality of life if not adequately treated.

The purpose of the study is to determine the short term safety, pharmacodynamic and clinical effect of AZD0284 in patients with psoriasis.

Conditions

  • Plaque Psoriasis Vulgaris

Interventions

DRUG

AZD0284 oral solution 2.5 mg/mL

AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks

DRUG

Placebo

Placebo for AZD0284 oral solution, twice daily for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Ioannis Psallidas, Phd · AstraZeneca R&D, Gothenburg, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-29
Primary Completion
2018-04-18
Completion
2018-04-18

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03310320 on ClinicalTrials.gov